LMNL Stock - Liminal BioSciences Inc.
Unlock GoAI Insights for LMNL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $401,000 | $643,000 | $3.32M | $4.90M | $47.37M |
| Gross Profit | $401,000 | $643,000 | $1.28M | $2.14M | $9.37M |
| Gross Margin | 100.0% | 100.0% | 38.7% | 43.7% | 19.8% |
| Operating Income | $-32,975,000 | $-49,557,000 | $-94,273,000 | $-210,630,000 | $-113,541,000 |
| Net Income | $-28,916,000 | $-45,063,000 | $-122,137,000 | $-234,224,000 | $-195,366,000 |
| Net Margin | -7211.0% | -7008.2% | -3682.2% | -4776.2% | -412.4% |
| EPS | $-341.80 | $-532.66 | $-1443.70 | $-2768.61 | $-2359.49 |
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Visit WebsiteEarnings History & Surprises
LMNLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 6, 2024 | — | — | — | — |
Q2 2024 | May 7, 2024 | — | — | — | — |
Q1 2024 | Mar 13, 2024 | — | — | — | — |
Q4 2023 | Nov 8, 2023 | — | — | — | — |
Q3 2023 | Aug 8, 2023 | — | $2.15 | — | — |
Q2 2023 | May 9, 2023 | — | $1.81 | — | — |
Q1 2023 | Mar 15, 2023 | — | $1.70 | — | — |
Q4 2022 | Nov 9, 2022 | — | $1.10 | — | — |
Q3 2022 | Aug 9, 2022 | — | $1.60 | — | — |
Q2 2022 | May 10, 2022 | — | $2.80 | — | — |
Q1 2022 | Mar 17, 2022 | $1.70 | $2.30 | +35.3% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $2.80 | $2.60 | -7.1% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $4.40 | $3.40 | -22.7% | ✗ MISS |
Q2 2021 | May 17, 2021 | $5.00 | $5.20 | +4.0% | ✓ BEAT |
Q1 2021 | Mar 24, 2021 | $5.70 | $6.20 | +8.8% | ✓ BEAT |
Q4 2020 | Nov 12, 2020 | $7.60 | $7.40 | -2.6% | ✗ MISS |
Q3 2020 | Aug 10, 2020 | — | $8.60 | — | — |
Q2 2020 | May 13, 2020 | — | $8.70 | — | — |
Q1 2020 | Mar 20, 2020 | — | $12.80 | — | — |
Q4 2019 | Nov 11, 2019 | — | $-9.54 | — | — |
Latest News
Frequently Asked Questions about LMNL
What is LMNL's current stock price?
What is the analyst price target for LMNL?
What sector is Liminal BioSciences Inc. in?
What is LMNL's market cap?
Does LMNL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LMNL for comparison